Segment Information

9 Months Ended

Sep. 30, 2012

Segment Information

Segment Information

Note 7. Segment Information

The Company operates in one business segment, which primarily focuses on the development and global commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. As of September 30, 2012, the majority of the Company’s product revenues have been derived from sales of one product, the Oncotype DX breast cancer test.

The following table summarizes total revenues from customers, payors and collaboration partners by geographic region. Product revenues are attributed to countries based on ship-to location. Contract revenues are attributed to countries based on the location of the collaboration partner.

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2012		2011		2012		2011
	(in thousands)
United States	$	50,564	$	46,966	$	155,798	$	138,853
Outside of the United States	8,084		5,092		18,948		13,860
Total revenues	$	58,648	$	52,058	$	174,746	$	152,713

Medicare payments for the three and nine months ended September 30, 2012 accounted for approximately 21% and 23%, respectively, of the Company’s product revenues compared to 22% and 21% for the three and nine months ended September 30, 2011, respectively. There were no other customers or payors who individually accounted for 10% or more of product revenues.